RAHUL AGGARWAL

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

64Cu-GRIP B in Patients With Advanced Malignancies

Phase 1

Recruiting

Conditions: Prostate Cancer
Renal Cancer
Urethral Cancer
Advanced Solid Tumor
Metastatic Castration-resistant Prostate Cancer
Solid Tumor, Adult

Interventions: Drug: Copper-64 labeled Granzyme B (64Cu-GRIP B)
Procedure: Positron Emission Tomography (PET)

First Posted Date: 2023-06-05

Last Posted Date: 2023-12-22

Lead Sponsor: Rahul Aggarwal

Target Recruit Count: 91

Registration Number: NCT05888532

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1

Recruiting

Conditions: Prostate Cancer
Metastatic Castration-resistant Prostate Cancer

Interventions: Biological: FOR46
Biological: Enzalutamide
Drug: Pegfilgrastim
Procedure: Blood Samples

First Posted Date: 2021-08-18

Last Posted Date: 2023-09-15

Lead Sponsor: Rahul Aggarwal

Target Recruit Count: 36

Registration Number: NCT05011188

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression

Phase 1

Recruiting

Conditions: Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8
Metastatic Castration-resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma
Stage IV Prostate Cancer AJCC v8
Metastatic Prostate Carcinoma
Solid Tumor, Adult
Solid Tumor

Interventions: Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Drug: 11C-YJH08
Procedure: Optional Tumor Biopsy

First Posted Date: 2021-06-16

Last Posted Date: 2024-05-29

Lead Sponsor: Rahul Aggarwal

Target Recruit Count: 26

Registration Number: NCT04927663

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Prostate Cancer
Small Cell Neuroendocrine Carcinoma
Small Cell Carcinoma

Interventions: Drug: Apalutamide
Biological: Cetrelimab

First Posted Date: 2021-06-15

Last Posted Date: 2024-04-26

Lead Sponsor: Rahul Aggarwal

Target Recruit Count: 2

Registration Number: NCT04926181

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 2

Recruiting

Conditions: Castration-Resistant Prostate Carcinoma
Metastatic Prostate Adenocarcinoma
Metastatic Prostate Small Cell Carcinoma
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8

Interventions: Drug: BET Bromodomain Inhibitor ZEN-3694
Drug: Enzalutamide
Biological: Pembrolizumab

First Posted Date: 2020-07-15

Last Posted Date: 2024-04-26

Lead Sponsor: Rahul Aggarwal

Target Recruit Count: 54

Registration Number: NCT04471974

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
University of Chicago, Evergreen Park, Illinois, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Phase 2

Recruiting

Conditions: Metastatic Urothelial Carcinoma
Stage III Pancreatic Cancer
Stage III Renal Cell Cancer
Stage IV Pancreatic Cancer
Stage IV Renal Cell Cancer
Metastatic Castration-resistant Prostate Cancer
Clear Cell Renal Cell Carcinoma
Locally Advanced Pancreatic Cancer
Metastatic Renal Cell Carcinoma
Metastatic Pancreatic Cancer

Interventions: Drug: Ceralasertib
Drug: Olaparib
Drug: Durvalumab

First Posted Date: 2018-09-24

Last Posted Date: 2023-12-13

Lead Sponsor: Rahul Aggarwal

Target Recruit Count: 89

Registration Number: NCT03682289

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Phase 1

Completed

Conditions: Stage IV Cutaneous Melanoma
Non-Small Cell Lung Carcinoma
Stage III Cutaneous Melanoma
Metastatic Urothelial Carcinoma
Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Stage III Lung Cancer AJCC v8
Stage III Ureter Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Stage IV Ureter Cancer AJCC v8

Interventions: Drug: Abexinostat
Biological: Pembrolizumab

First Posted Date: 2018-07-18

Last Posted Date: 2024-03-22

Lead Sponsor: Rahul Aggarwal

Target Recruit Count: 35

Registration Number: NCT03590054

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Pyruvate (13C)
Device: MRI

First Posted Date: 2016-09-23

Last Posted Date: 2022-04-22

Lead Sponsor: Rahul Aggarwal

Target Recruit Count: 23

Registration Number: NCT02913131

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Pyruvate (13C)
Device: MRI

First Posted Date: 2016-09-22

Last Posted Date: 2020-07-24

Lead Sponsor: Rahul Aggarwal

Target Recruit Count: 8

Registration Number: NCT02911467

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Docetaxel-PNP
Drug: Ribociclib
Drug: Prednisone
Drug: Filgrastim

First Posted Date: 2015-07-10

Last Posted Date: 2022-08-31

Lead Sponsor: Rahul Aggarwal

Target Recruit Count: 43

Registration Number: NCT02494921

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

and more 3 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy